DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Börse Stuttgart 15:20:14 2024-07-05 EDT | ||
| 0.036 EUR | +20.00% |
|
| Current month | -7.69% | ||
| 1 month | -10.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.036 | +20.00% |
| 24-07-04 | 0.03 | -14.29% |
| 24-07-03 | 0.035 | -5.41% |
| 24-07-02 | 0.037 | -7.50% |
| 24-07-01 | 0.04 | +2.56% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 03:20 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME21ZX |
| ISIN | DE000ME21ZX7 |
| Date issued | 2023-10-13 |
| Strike | 75 $ |
| Maturity | 2024-09-20 (77 Days) |
| Parity | 10 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.212 € |
|---|---|
| Lowest since issue | 0.022 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
